{
    "type": "ETP",
    "ucits": false,
    "replication_method": "physical",
    "leverage": true,
    "derivatives": false,
    "swaps": false,
    "inverse": false,
    "complex_factors": [
        "Leverage",
        "Daily Compounding",
        "Margin Borrowing"
    ],
    "classification": "complex",
    "supporting_data": "The product is a Collateralised Exchange Traded Security (ETP) that seeks to provide 3x the daily performance of Moderna Inc. stock by physically holding the underlying shares and using margin borrowing to amplify exposure. The replication method is physical, with no indication of synthetic replication or swap usage. However, the product employs leverage of 3x, daily rebalancing, and compounding effects, which significantly increase complexity. The risk indicator is at the highest level (7/7), reflecting the amplified risk and potential for significant losses. The product is not UCITS compliant and is intended for sophisticated investors who understand leverage and daily compounding risks. There is no capital protection, and the product may be difficult to understand for retail investors. No derivatives or swap agreements are used inherently in the strategy, but margin borrowing (gearing) is employed to achieve leverage. The complexity arises primarily from the leveraged exposure, daily compounding effects, and the sophisticated nature of the product rather than derivative or swap usage. The PRIIPs KID and factsheet confirm physical replication and margin use, with no synthetic or swap structures. The product's complexity is driven by leverage and the associated risks rather than derivative instruments."
}